Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
B & L Soothe Lubricant Eye · 1 trial · 1 indication
The wavefront sensor instrument measures the eye's ability to create a sharp image. Ellipsometer (E) data identifies changes in lipid thickness and refractive index over the cornea. A thermal (T) imaging system provides thermal maps of the subject's eyes and face adjacent to the eyes. A questionnaire (Q) will ask subjects about their test eye's comfort. Subjects will be asked the questions prior to instillation of the eye drop and after each set of measurements.
| Arm | Type | Description |
|---|---|---|
| Drop Administration | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| B & L Soothe Lubricant Eye Drops | DRUG | Eye Drop |
| Liposic EDO | DRUG | Eye Drop |
| OcuFresh Eye Wash | DRUG | Saline drop |
Inclusion Criteria: * Age 30-75 years * Good general health * Willing to spend time for the study; approximately one hour for a screening visit and 90 minutes for each of the measurement visits * Currently using an OTC artificial tear for ocular comfort, at least occasionally. * At least one positi...
B & L Soothe Lubricant Eye is used for dry eye. It is an investigational small molecule being developed by Bausch + Lomb Corporation for the treatment of dry eye. The drug is currently in early Phase 1 clinical development.
Bausch + Lomb Corporation (NYSE: BLCO) is developing B & L Soothe Lubricant Eye. The company is conducting clinical research on this lubricant eye product for dry eye.
B & L Soothe Lubricant Eye is in early Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. One early Phase 1 trial has been completed.
B & L Soothe Lubricant Eye has one completed clinical trial, NCT01375582, titled "Objective Evaluation of Ocular Surface Lubricants in Two Environments." This early Phase 1 study enrolled 20 participants with dry eye in the United States.
B & L Soothe Lubricant Eye is not FDA approved. It is an investigational product currently in early Phase 1 clinical development. The completed trial was a double-blind, uncontrolled study evaluating the ocular surface lubricant.